Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Life SciencesNSE:SAILIFE +2.51%18 EBIT per Share is ₹23.67 as of Mar. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 94.55% on this metric.
Sai Life Sciences's EBIT per Share for the
three
months ended in Mar. 2026 was ₹6.87.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹23.67.
During the past 12 months, the average EBIT per Share Growth Rate of Sai Life Sciences was 61.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 80.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sai Life Sciences's EBIT per Share or its related term are showing as below:
NSE:SAILIFE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 80.9 Med: 90.15 Max: 99.4
Current: 80.9
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Sai Life Sciences was 99.40% per year. The lowest was 80.90% per year. And the median was 90.15% per year.
NSE:SAILIFE's 3-Year EBIT Growth Rate is ranked better than 94.55% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs NSE:SAILIFE: 80.90
Sai Life Sciences (NSE:SAILIFE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sai Life Sciences EBIT per Share Related Terms
Sai Life Sciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹23.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences (NSE:SAILIFE) has a EBIT per Share of ₹23.67 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sai Life Sciences and its competitors. According to the industry distribution chart, Sai Life Sciences ranks #9 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 5.5%.
Is Sai Life Sciences' EBIT per Share too high?
Sai Life Sciences' current EBIT per Share is ₹23.67. Based on the distribution chart, Sai Life Sciences ranks #9 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #9 out of 165 companies for EBIT per Share. This places Sai Life Sciences in the top 6% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current EBIT per Share is ₹23.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current EBIT per Share of ₹23.67. The current EBIT per Share is ₹23.67. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current EBIT per Share is ₹23.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
